Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-Bound Fibrin Sealant During Liver Resection
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This is a multi-centre, patient-blinded, intra-operatively randomised controlled trial. A
total of 126 patients planned for an elective liver resection will be enrolled in 9 surgical
centres. The primary objective of this study is to show that the collagen based haemostatic
device Sangustop® is not inferior to a carrier-bound fibrin sealant (Tachosil®) in achieving
haemostasis after hepatic resection.